MedTrace Logo

Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease

NCT04523727 · Status: SUSPENDED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-05-14

No results posted yet for this study

Summary

This study will be conducted to assess the safety and tolerability of ferric citrate in pediatric participants with hyperphosphatemia related to chronic kidney disease (CKD).

Conditions

  • Hyperphosphatemia Related to Chronic Kidney Disease

Interventions

DRUG

ferric citrate

oral tablets

Sponsors & Collaborators

  • Keryx Biopharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Chief Medical Officer · Akebia Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-16
Primary Completion
2026-12-31
Completion
2027-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04523727 on ClinicalTrials.gov